دورية أكاديمية
أعرض في EDS

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).

التفاصيل البيبلوغرافية
العنوان: SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
المؤلفون: Gómez-España MA; Medical Oncology Department, Hospital Universitario Reina Sofía, IMIBIC, CIBERONC, Córdoba, Spain. magespanya@hotmail.com., Montes AF; Medical Oncology Department, Complexo Hospitalario Universitario de Ourense (CHUO), Orense, Spain., Garcia-Carbonero R; Medical Oncology Department, Hospital Universitario, UCM, CNIO, CIBERONC, 12 de Octubre, IIS imas12, Madrid, Spain., Mercadé TM; Medical Oncology Department, Hospital Universitari Vall D´Hebron, Barcelona, Spain., Maurel J; Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain., Martín AM; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Pazo-Cid R; Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain., Vera R; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain., Carrato A; Medical Oncology Department, Hospital Universitario Ramón Y Cajal, Alcala University, IRYCIS, CIBERONC, Madrid, Spain., Feliu J; Medical Oncology Department, Hospital Universitario La Paz, CIBERONC, IDIPAZ, Madrid, Spain.
المصدر: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2021 May; Vol. 23 (5), pp. 988-1000. Date of Electronic Publication: 2021 Mar 03.
نوع المنشور: Journal Article; Practice Guideline
اللغة: English
بيانات الدورية: Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2010- >: Milan : Springer Italia
Original Publication: Barcelona, Spain : Doyma, c2005-
مواضيع طبية MeSH: Biliary Tract Neoplasms/*therapy , Pancreatic Neoplasms/*therapy, Albumins/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biliary Tract Neoplasms/genetics ; Biliary Tract Neoplasms/pathology ; Biliary Tract Neoplasms/surgery ; Capecitabine/therapeutic use ; Chemoradiotherapy/methods ; Chemotherapy, Adjuvant/methods ; Cisplatin/therapeutic use ; Fluorouracil/therapeutic use ; Humans ; Irinotecan/therapeutic use ; Leucovorin/therapeutic use ; Medical Oncology ; Neoadjuvant Therapy/methods ; Neoplasm Staging ; Oxaliplatin/therapeutic use ; Paclitaxel/therapeutic use ; Palliative Care ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/pathology ; Pancreatic Neoplasms/surgery ; Quality of Life ; Societies, Medical ; Spain
مستخلص: Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. Surgery is the only potentially curative therapy in both cancers, but disease recurrence is frequent. In PC, adjuvant treatment with mFOLFIRINOX has improved overall survival (OS) and in BTC adjuvant treatment with capecitabine seems to improve OS and relapse-free survival. Concomitant radio-chemotherapy could also be considered following R1 surgery in both neoplasms. Neoadjuvant treatment represents the best option for achieving an R0 resection in borderline PC. Upfront systemic chemotherapy is the treatment of choice in unresectable locally advanced PC and BTC; then locoregional therapy could be considered after an initial period of at least 3-4 months of systemic chemotherapy. In metastatic PC, FOLFIRINOX or Gemcitabine plus nab-paclitaxel have improved OS compared with gemcitabine alone. In metastatic BTC, cisplatin plus gemcitabine constitute the standard treatment. Progress in the knowledge of molecular biology has enabled the identification of new targets for therapy with encouraging results that could in the future improve the survival and quality of life of patients with PC and BTC.
References: J Clin Oncol. 2015 Aug 20;33(24):2617-22. (PMID: 25964250)
J Hepatol. 2014 Jun;60(6):1268-89. (PMID: 24681130)
Discov Med. 2019 Nov-Dec;28(155):255-265. (PMID: 32053766)
JAMA. 2016 May 3;315(17):1844-53. (PMID: 27139057)
J Clin Oncol. 2008 Jul 20;26(21):3496-502. (PMID: 18640930)
Lancet Oncol. 2013 Apr;14(4):317-26. (PMID: 23474363)
Cell. 2012 Jan 20;148(1-2):349-61. (PMID: 22265420)
N Engl J Med. 2018 Dec 20;379(25):2395-2406. (PMID: 30575490)
Lancet Oncol. 2020 Jun;21(6):796-807. (PMID: 32416072)
Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):207-220. (PMID: 30718832)
Cancer Discov. 2017 Apr;7(4):400-409. (PMID: 28183697)
Am Soc Clin Oncol Educ Book. 2016;35:e194-203. (PMID: 27249723)
Cancer Treat Rev. 2018 Nov;70:168-177. (PMID: 30218788)
Clin Cancer Res. 2020 Sep 15;26(18):4901-4910. (PMID: 32156747)
Lancet. 2017 Mar 11;389(10073):1011-1024. (PMID: 28129987)
Lancet Oncol. 2019 May;20(5):663-673. (PMID: 30922733)
N Engl J Med. 2011 May 12;364(19):1817-25. (PMID: 21561347)
J Clin Oncol. 2010 Oct 20;28(30):4581-6. (PMID: 20855823)
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111. (PMID: 28994423)
Pancreatology. 2019 Jan;19(1):114-121. (PMID: 30385188)
J Clin Oncol. 2020 Jun 1;38(16):1763-1773. (PMID: 32105518)
Chin Clin Oncol. 2019 Aug;8(4):42. (PMID: 31431036)
Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):348-351. (PMID: 29339358)
Br J Cancer. 2010 Aug 10;103(4):469-74. (PMID: 20628385)
Ann Surg Treat Res. 2018 Apr;94(4):190-195. (PMID: 29629353)
Lancet. 2016 Feb 6;387(10018):545-557. (PMID: 26615328)
Lancet Oncol. 2020 May;21(5):671-684. (PMID: 32203698)
Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007519. (PMID: 21412903)
N Engl J Med. 2018 Feb 22;378(8):731-739. (PMID: 29466156)
J Clin Oncol. 2020 Jan 1;38(1):1-10. (PMID: 31682550)
Science. 2020 May 29;368(6494):973-980. (PMID: 32467386)
JCO Precis Oncol. 2020 Nov;4:426-436. (PMID: 35050739)
Eur J Cancer. 2016 Dec;69:110-118. (PMID: 27821313)
Radiographics. 2008 Sep-Oct;28(5):1263-87. (PMID: 18794305)
Ann Surg Oncol. 2015 Oct;22(11):3409-13. (PMID: 26122369)
Ann Oncol. 1996 Aug;7(6):593-600. (PMID: 8879373)
Ann Oncol. 2014 Feb;25(2):391-8. (PMID: 24351397)
N Engl J Med. 2019 Jul 25;381(4):317-327. (PMID: 31157963)
Br J Surg. 2014 Jul;101(8):1000-5. (PMID: 24844590)
Clin Cancer Res. 2019 Apr 15;25(8):2450-2457. (PMID: 30573691)
AJR Am J Roentgenol. 2008 Nov;191(5):1440-7. (PMID: 18941083)
Br J Cancer. 2007 Mar 26;96(6):896-902. (PMID: 17325704)
Ann Surg Oncol. 2008 Jun;15(6):1651-60. (PMID: 18351300)
J Clin Oncol. 2012 Jun 1;30(16):1934-40. (PMID: 22529261)
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):934-947. (PMID: 31648972)
Ann Oncol. 2017 Oct 01;28(10):2340-2366. (PMID: 28945867)
Lancet Oncol. 2015 Jan;16(1):36-46. (PMID: 25467404)
Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308)
N Engl J Med. 2010 Apr 8;362(14):1273-81. (PMID: 20375404)
N Engl J Med. 2013 Oct 31;369(18):1691-703. (PMID: 24131140)
Clin Gastroenterol Hepatol. 2004 Apr;2(4):273-85. (PMID: 15067620)
فهرسة مساهمة: Keywords: Biliary tract cancer; Chemotherapy; Pancreatic cancer; Radiotherapy; Treatment
المشرفين على المادة: 0 (130-nm albumin-bound paclitaxel)
0 (Albumins)
0 (folfirinox)
04ZR38536J (Oxaliplatin)
6804DJ8Z9U (Capecitabine)
7673326042 (Irinotecan)
P88XT4IS4D (Paclitaxel)
Q20Q21Q62J (Cisplatin)
Q573I9DVLP (Leucovorin)
U3P01618RT (Fluorouracil)
تواريخ الأحداث: Date Created: 20210304 Date Completed: 20210830 Latest Revision: 20240401
رمز التحديث: 20240401
مُعرف محوري في PubMed: PMC8058005
DOI: 10.1007/s12094-021-02573-1
PMID: 33660222
قاعدة البيانات: MEDLINE
الوصف
تدمد:1699-3055
DOI:10.1007/s12094-021-02573-1